MedDataX Logo

Study Evaluating Rapamune in Patients After Kidney Transplantation

NCT ID: NCT00240214

Last Updated: 2008-03-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-04-30

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Rapamune® Maintenance Regimen

NCT00478608

Renal Transplant
COMPLETED PHASE3

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

NCT00037531

Graft vs Host Disease Kidney Transplantation
COMPLETED PHASE3

Study Investigating Rapamune For Post-Marketing Surveillance

NCT00484094

Kidney Transplantation
COMPLETED

Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus

NCT00248313

Kidney Disease
COMPLETED PHASE3

Study Evaluating Sirolimus in Kidney Transplant Recipients in India

NCT00195481

Kidney Failure Graft vs Host Disease
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

sirolimus

sirolimus

Intervention Type DRUG

Tablet, dosage is determined by trough level

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sirolimus

Tablet, dosage is determined by trough level

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes.

Exclusion Criteria

* Contraindications according to Summary of the Product Characteristics (SmPC).
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wyeth

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Germany, [email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Multiple Cities, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0468E-100875

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
NCT00086346 TERMINATED PHASE3
Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries
NCT00195195 COMPLETED
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
NCT00123331 COMPLETED PHASE4
Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation
NCT00811915 COMPLETED PHASE3
Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients
NCT00519116 COMPLETED PHASE4
Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients
NCT00518271 COMPLETED PHASE2
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
NCT00044720 COMPLETED PHASE4
Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants
NCT00257387 COMPLETED PHASE1/PHASE2
Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients
NCT00306397 COMPLETED PHASE4
Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients
NCT00252655 UNKNOWN PHASE4
Efficacy and Safety of Sirolimus in Combination With Tacrolimus
NCT00141804 UNKNOWN PHASE3
Study Evaluating Sirolimus in Kidney Transplant Recipients.
NCT00167947 COMPLETED PHASE3
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
NCT00273871 COMPLETED PHASE3
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
NCT02057484 COMPLETED
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
NCT00866879 COMPLETED PHASE4
Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients
NCT00470665 COMPLETED PHASE3
Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
NCT00428064 COMPLETED PHASE3
Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients
NCT00204321 COMPLETED PHASE4
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
NCT00768729 COMPLETED PHASE1
Calcineurin Free Immunosuppression in Renal Transplant Recipients
NCT00812123 COMPLETED PHASE4
Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
NCT02311010 UNKNOWN PHASE4
A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients
NCT01742676 COMPLETED PHASE4
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation
NCT01742624 COMPLETED PHASE4
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
NCT01236378 COMPLETED PHASE1
The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
NCT00275535 COMPLETED PHASE4